Ross M. Maltz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ross M. Maltz has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
Brendan Boyle
Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Nationwide Children’s Hospital , Columbus, OH
6 shared publicationsMegan McNicol
Department of Pharmacy, Nationwide Children’s Hospital , Columbus, OH
5 shared publicationsGrant A. Morris
Division of Pediatric Gastroenterology, Hepatology and Nutrition Geisinger Janet Weis Children's Hospital Danville Pennsylvania USA
3 shared publicationsHilary K. Michel
Division of Pediatric Gastroenterology, Hepatology, and Nutrition Nationwide Children's Hospital Columbus Ohio USA
3 shared publications- Hilary K. Michel
Nationwide Children's Hospital Columbus Ohio USA
3 shared publications Jennifer L. Dotson
Division of Pediatric Gastroenterology, Hepatology, and Nutrition Nationwide Children's Hospital Columbus Ohio USA
3 shared publications
Latest Publications
- 31 July 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Infliximab originator and biosimilars have similar efficacy in children with inflammatory bowel disease
Objectives: To evaluate whether children with inflammatory bowel disease (IBD) who initiate infliximab originator versus biosimilar experience similar clinical outcomes at 12 months. Methods: We conducted a retrospective cohort study evaluating prospectively collected data from the ImproveCareNow (ICN) Network registry. Children χ 2 , Fisher's exact test, or Wilcoxon rank sum test. Cox proportional hazard models were created to compare time to drug discontinuation, hospitalizations, and surgery between the two groups. Results: After propensity score matching, 428 children were included, 214 originator and 214 biosimilar starters. Efficacy at 12 months was similar as assessed by steroid‐free clinical remission ( p = 0.25), height‐ z ‐score ( p = 0.68), hematocrit ( p = 0.37), albumin ( p = 0.40), and erythrocyte sedimentation rate ( p = 0.06). Time to infliximab discontinuation ( p = 0.21), time to surgery ( p = 0.79), and time to hospitalization ( p = 0.66) were comparable between infliximab originator and biosimilar users. Fecal calprotectin values were statistically higher ( p = 0.032) at 12 months in patients started on the infliximab biosimilar versus originator, but only 30% of patients had values. Conclusion: This is one of the largest, multicenter studies to evaluate infliximab biosimilar use. Rigorous propensity score‐matched methods demonstrated no differences in outcomes or treatment durability between children with IBD initiating infliximab originator or biosimilars.
- 31 July 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Infliximab originator and biosimilars have similar efficacy in children with inflammatory bowel disease
Objectives: To evaluate whether children with inflammatory bowel disease (IBD) who initiate infliximab originator versus biosimilar experience similar clinical outcomes at 12 months. Methods: We conducted a retrospective cohort study evaluating prospectively collected data from the ImproveCareNow (ICN) Network registry. Children χ 2 , Fisher's exact test, or Wilcoxon rank sum test. Cox proportional hazard models were created to compare time to drug discontinuation, hospitalizations, and surgery between the two groups. Results: After propensity score matching, 428 children were included, 214 originator and 214 biosimilar starters. Efficacy at 12 months was similar as assessed by steroid‐free clinical remission ( p = 0.25), height‐ z ‐score ( p = 0.68), hematocrit ( p = 0.37), albumin ( p = 0.40), and erythrocyte sedimentation rate ( p = 0.06). Time to infliximab discontinuation ( p = 0.21), time to surgery ( p = 0.79), and time to hospitalization ( p = 0.66) were comparable between infliximab originator and biosimilar users. Fecal calprotectin values were statistically higher ( p = 0.032) at 12 months in patients started on the infliximab biosimilar versus originator, but only 30% of patients had values. Conclusion: This is one of the largest, multicenter studies to evaluate infliximab biosimilar use. Rigorous propensity score‐matched methods demonstrated no differences in outcomes or treatment durability between children with IBD initiating infliximab originator or biosimilars.
- Open Access
- 8 July 2026
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 8 (3)
Induction-phase infliximab monitoring accelerates time to remission in pediatric IBD: a retrospective cohort study
Background: In pediatric inflammatory bowel disease (IBD), the optimal timing to begin therapeutic drug monitoring (TDM) of infliximab (IFX) is unclear. We hypothesized that TDM during induction of IFX improves clinical outcomes in children with IBD. Methods: This retrospective cohort study utilized data from an internal database at Nationwide Children’s Hospital between January 1, 2020, and December 31, 2023. Pediatric IBD patients receiving IFX with induction-phase TDM (I-TDM) at Week 6 were compared to those with maintenance-phase TDM (M-TDM) at Week 14. Propensity score matching (PSM) was used for sex, disease, and age at IFX start. The primary outcome was time to clinical remission. Results: In total, 68 patients were matched from each group. The I-TDM group experienced a shorter median time to clinical remission (140 days [95% CI: 108, 167]) compared to the M-TDM group (203 days [95% CI: 167, 232]; P = .006). When adjusting for baseline variations, I-TDM remained independently associated with accelerated clinical remission (aHR = 1.68, 95% CI: 1.10, 2.55; P = .016). While time to therapeutic maintenance IFX levels was similar, post hoc analysis showed that 75% of patients in the I-TDM group achieved target levels in 134 days (95% CI: 114, 182) versus 183 days (95% CI: 153, 224) in the M-TDM group. There were no significant differences in long-term complications between the groups. Conclusions: Induction-phase TDM before the third infusion shortens the time to clinical remission, allowing for more prompt dose adjustments and improving patient outcomes. This approach warrants consideration in clinical practice for children with IBD.
- 8 July 2026
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 8 (3)
Open AccessInduction-phase infliximab monitoring accelerates time to remission in pediatric IBD: a retrospective cohort study
Background: In pediatric inflammatory bowel disease (IBD), the optimal timing to begin therapeutic drug monitoring (TDM) of infliximab (IFX) is unclear. We hypothesized that TDM during induction of IFX improves clinical outcomes in children with IBD. Methods: This retrospective cohort study utilized data from an internal database at Nationwide Children’s Hospital between January 1, 2020, and December 31, 2023. Pediatric IBD patients receiving IFX with induction-phase TDM (I-TDM) at Week 6 were compared to those with maintenance-phase TDM (M-TDM) at Week 14. Propensity score matching (PSM) was used for sex, disease, and age at IFX start. The primary outcome was time to clinical remission. Results: In total, 68 patients were matched from each group. The I-TDM group experienced a shorter median time to clinical remission (140 days [95% CI: 108, 167]) compared to the M-TDM group (203 days [95% CI: 167, 232]; P = .006). When adjusting for baseline variations, I-TDM remained independently associated with accelerated clinical remission (aHR = 1.68, 95% CI: 1.10, 2.55; P = .016). While time to therapeutic maintenance IFX levels was similar, post hoc analysis showed that 75% of patients in the I-TDM group achieved target levels in 134 days (95% CI: 114, 182) versus 183 days (95% CI: 153, 224) in the M-TDM group. There were no significant differences in long-term complications between the groups. Conclusions: Induction-phase TDM before the third infusion shortens the time to clinical remission, allowing for more prompt dose adjustments and improving patient outcomes. This approach warrants consideration in clinical practice for children with IBD.
- Open Access
Esophageal Eosinophilia in Pediatric and Young Adult Patients with Inflammatory Bowel Disease: Diagnosis, Clinical Course, and Treatment Outcomes
Background/Objectives: This study evaluates the clinical presentation and treatment outcomes of esophageal eosinophilia (EE) in patients with inflammatory bowel disease (IBD). It compares outcomes based on the timing of diagnosis (simultaneous vs. EE after IBD diagnosis) and treatment (treated vs. untreated EE). Methods: This retrospective cohort study included patients ≤ 22 years with IBD and EE (≥15 eosinophils/high-powered field {eos/HPF}) between July 2017 and December 2023. Clinical, endoscopic, histologic, and EE treatment data were collected. EE histologic remission defined as p < 0.05 considered significant. Results: Of fifty-six patients with IBD and EE, thirteen (23%) were diagnosed with EE and IBD simultaneously and forty-three (77%) patients were diagnosed with EE after IBD. Most were diagnosed with EE incidentally. Esophageal symptoms and histologic findings between patients diagnosed simultaneously vs. EE after IBD were similar. Among patients treated for EE (n = 28) and those who were untreated (n = 28), there were significant differences in esophageal symptoms (54% vs. 0%; p < 0.01) and median esophageal eosinophil count (30 vs. 22 eos/HPF; p = 0.003). However, among patients with a repeat EGD, EE histologic remission rates were similar between those who were treated vs. untreated (35% vs. 47%; p = 0.5). Conclusions: We found that for patients with both IBD and EE, most were diagnosed incidentally with EE after IBD diagnosis. The observation of spontaneous histologic esophageal remission in a subset of patients suggests that incidental EE in patients with IBD may not always represent eosinophilic esophagitis (EoE) and should not automatically lead to a lifelong diagnosis.
Open AccessEsophageal Eosinophilia in Pediatric and Young Adult Patients with Inflammatory Bowel Disease: Diagnosis, Clinical Course, and Treatment Outcomes
Background/Objectives: This study evaluates the clinical presentation and treatment outcomes of esophageal eosinophilia (EE) in patients with inflammatory bowel disease (IBD). It compares outcomes based on the timing of diagnosis (simultaneous vs. EE after IBD diagnosis) and treatment (treated vs. untreated EE). Methods: This retrospective cohort study included patients ≤ 22 years with IBD and EE (≥15 eosinophils/high-powered field {eos/HPF}) between July 2017 and December 2023. Clinical, endoscopic, histologic, and EE treatment data were collected. EE histologic remission defined as p < 0.05 considered significant. Results: Of fifty-six patients with IBD and EE, thirteen (23%) were diagnosed with EE and IBD simultaneously and forty-three (77%) patients were diagnosed with EE after IBD. Most were diagnosed with EE incidentally. Esophageal symptoms and histologic findings between patients diagnosed simultaneously vs. EE after IBD were similar. Among patients treated for EE (n = 28) and those who were untreated (n = 28), there were significant differences in esophageal symptoms (54% vs. 0%; p < 0.01) and median esophageal eosinophil count (30 vs. 22 eos/HPF; p = 0.003). However, among patients with a repeat EGD, EE histologic remission rates were similar between those who were treated vs. untreated (35% vs. 47%; p = 0.5). Conclusions: We found that for patients with both IBD and EE, most were diagnosed incidentally with EE after IBD diagnosis. The observation of spontaneous histologic esophageal remission in a subset of patients suggests that incidental EE in patients with IBD may not always represent eosinophilic esophagitis (EoE) and should not automatically lead to a lifelong diagnosis.
- 5 May 2026
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 83 (21) , e821-e829
Evaluating prescribing and access trends for adalimumab biosimilars in pediatric and adolescent care
Purpose: The expiration of market exclusivity for Humira (adalimumab) in February 2023 led to the introduction of 10 biosimilars, raising questions about their impact on prescribing trends, payer responses, and formulary management in pediatrics. The primary objective of this study was to compare time to prior authorization approval between adalimumab biosimilars and the originator product during the first 2.5 years following biosimilar market entry. Secondary objectives were to describe the reason for switching adalimumab products in those already established on adalimumab therapy and to identify reported intolerances associated with biosimilar products. Methods: To prepare for biosimilar launches, the clinical pharmacy team provided education to clinic staff and the health-system specialty pharmacy (HSSP), engaged with manufacturers to identify resources related to biosimilar products, and established prescribing workflows for patients on adalimumab. An observational study was then conducted from February 1, 2023, to June 30, 2025, across dermatology, gastroenterology, and rheumatology outpatient clinics of an integrated HSSP to assess biosimilar prescribing trends, time to authorization approval, and reason for switches. Included prescriptions were for patients naïve to adalimumab or switching between adalimumab products. Results: Evaluation of 350 prescriptions for adalimumab-naïve patients found that Humira was the preferred product for 290 prescriptions (82.9%). In adalimumab-naïve patients, the median time to prior authorization approval was 4 days (interquartile range [IQR], 2-9 days), with no significant difference between Humira (4 days; IQR, 2-10 days) and biosimilars (3 days; IQR, 2-9 days; P = 0.39). Among 256 prescriptions for non–adalimumab-naïve patients, the majority (86%) were for switches from Humira to a biosimilar, primarily due to formulary preference (77%), new insurance for the patient (11.3%), or exhaustion of copay card funds (4.7%). Conclusion: Despite inherent complexities of biosimilar implementation, this study demonstrates that a coordinated, pharmacist-led approach supports timely access to therapy and minimizes treatment delays.
- 5 May 2026
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 83 (21) , e821-e829
Evaluating prescribing and access trends for adalimumab biosimilars in pediatric and adolescent care
Purpose: The expiration of market exclusivity for Humira (adalimumab) in February 2023 led to the introduction of 10 biosimilars, raising questions about their impact on prescribing trends, payer responses, and formulary management in pediatrics. The primary objective of this study was to compare time to prior authorization approval between adalimumab biosimilars and the originator product during the first 2.5 years following biosimilar market entry. Secondary objectives were to describe the reason for switching adalimumab products in those already established on adalimumab therapy and to identify reported intolerances associated with biosimilar products. Methods: To prepare for biosimilar launches, the clinical pharmacy team provided education to clinic staff and the health-system specialty pharmacy (HSSP), engaged with manufacturers to identify resources related to biosimilar products, and established prescribing workflows for patients on adalimumab. An observational study was then conducted from February 1, 2023, to June 30, 2025, across dermatology, gastroenterology, and rheumatology outpatient clinics of an integrated HSSP to assess biosimilar prescribing trends, time to authorization approval, and reason for switches. Included prescriptions were for patients naïve to adalimumab or switching between adalimumab products. Results: Evaluation of 350 prescriptions for adalimumab-naïve patients found that Humira was the preferred product for 290 prescriptions (82.9%). In adalimumab-naïve patients, the median time to prior authorization approval was 4 days (interquartile range [IQR], 2-9 days), with no significant difference between Humira (4 days; IQR, 2-10 days) and biosimilars (3 days; IQR, 2-9 days; P = 0.39). Among 256 prescriptions for non–adalimumab-naïve patients, the majority (86%) were for switches from Humira to a biosimilar, primarily due to formulary preference (77%), new insurance for the patient (11.3%), or exhaustion of copay card funds (4.7%). Conclusion: Despite inherent complexities of biosimilar implementation, this study demonstrates that a coordinated, pharmacist-led approach supports timely access to therapy and minimizes treatment delays.
- Open Access
- 8 January 2026
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 8 (1)
Young Adults with Inflammatory Bowel Disease in the US Experience Gaps in Healthcare Access and Financial Stress: Additional Findings from a Recent Survey by the Crohn’s & Colitis Foundation
Background: Young adults with chronic conditions are at increased risk for active disease and for poor adherence, resulting in increased emergency department utilization and hospitalizations. We aimed to evaluate whether young adults with inflammatory bowel disease (IBD) experienced more healthcare access challenges and financial distress compared to adults and pediatric patients. Methods: A survey developed by the Crohn’s & Colitis Foundation was electronically disseminated to adults with IBD and caregivers across the United States to assess healthcare access and financial challenges. Analyses were completed to evaluate differences across patient age groups (caregivers on behalf of pediatric patients <18 years, young adults 18-25 years, and adults 26-64 years) using Chi square or Fisher’s exact tests. Results: Of 1781 respondents (77% adult, 12.9% young adult, and 10.1% pediatric caregivers), there were no significant differences between groups in obtaining insurance approval and experiencing adverse health events due to treatment delays. However, young adults were more likely to experience step therapy mandates and less likely to know what questions to ask their insurer if experiencing coverage problems compared to adult and pediatric patients’ caregivers. Additionally, young adult patients were more likely to take on an extra job or work more hours to afford their healthcare or insurance costs related to IBD. Conclusion: Additional analysis from the Crohn’s & Colitis Foundation access assessment highlights the need for more resources and support in navigating healthcare access for young adult patients with IBD.
- 8 January 2026
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 8 (1)
Open AccessYoung Adults with Inflammatory Bowel Disease in the US Experience Gaps in Healthcare Access and Financial Stress: Additional Findings from a Recent Survey by the Crohn’s & Colitis Foundation
Background: Young adults with chronic conditions are at increased risk for active disease and for poor adherence, resulting in increased emergency department utilization and hospitalizations. We aimed to evaluate whether young adults with inflammatory bowel disease (IBD) experienced more healthcare access challenges and financial distress compared to adults and pediatric patients. Methods: A survey developed by the Crohn’s & Colitis Foundation was electronically disseminated to adults with IBD and caregivers across the United States to assess healthcare access and financial challenges. Analyses were completed to evaluate differences across patient age groups (caregivers on behalf of pediatric patients <18 years, young adults 18-25 years, and adults 26-64 years) using Chi square or Fisher’s exact tests. Results: Of 1781 respondents (77% adult, 12.9% young adult, and 10.1% pediatric caregivers), there were no significant differences between groups in obtaining insurance approval and experiencing adverse health events due to treatment delays. However, young adults were more likely to experience step therapy mandates and less likely to know what questions to ask their insurer if experiencing coverage problems compared to adult and pediatric patients’ caregivers. Additionally, young adult patients were more likely to take on an extra job or work more hours to afford their healthcare or insurance costs related to IBD. Conclusion: Additional analysis from the Crohn’s & Colitis Foundation access assessment highlights the need for more resources and support in navigating healthcare access for young adult patients with IBD.
- 12 November 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 82 (1) , 103-107
Clinical characteristics and 1‐year outcomes of patients with autism spectrum disorder and inflammatory bowel disease
- 12 November 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 82 (1) , 103-107
Clinical characteristics and 1‐year outcomes of patients with autism spectrum disorder and inflammatory bowel disease
- 21 July 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (4) , 1024-1033
Predictors of antitumor necrosis factor primary nonresponse and drug durability in pediatric inflammatory bowel disease
Objectives: Antitumor necrosis factor (anti‐TNF) therapies are first‐line therapies for children with inflammatory bowel disease (IBD) (Crohn's disease [CD], ulcerative colitis [UC] and IBD‐unclassified [IBD‐U]). Limited studies describing anti‐TNFs durability and loss of response in children. This study evaluates predictors of primary Nonresponse and 3‐year drug durability in children with IBD.Methods: This was a single‐center retrospective review of patients with IBD less than 18 years old who initiated anti‐TNF (infliximab or adalimumab) from January 1, 2014, to December 31, 2019. Clinical and laboratory data were recorded at the time of anti‐TNF initiation, 14 weeks, 12 months, and 3 years. Predictors of primary nonresponse (discontinuation within 14 weeks) and durability were assessed.Results: A total of 456 patients initiated anti‐TNF therapy (183 adalimumab and 273 infliximab). Thirty‐seven (8%) patients were primary nonresponders. The 3‐year drug durability for both therapies was >70%. Among patients with CD, the 3‐year durability was >75% for both therapies. The 3‐year durability with UC/IBD‐U was 37% for adalimumab and 56% for infliximab. Predictors of primary nonresponse were an erythrocyte sedimentation rate > 55 mm/h in CD on infliximab, and baseline albumin <4 g/dL and 75% in patients with CD, while the durability was lower (37%–56%) for patients with UC/IBD‐U. Less than 10% of patients were considered primary nonresponders, which lends support to the long‐term durability of anti‐TNF therapies for pediatric IBD while keeping in mind predictive factors of Nonresponse.
- 21 July 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (4) , 1024-1033
Predictors of antitumor necrosis factor primary nonresponse and drug durability in pediatric inflammatory bowel disease
Objectives: Antitumor necrosis factor (anti‐TNF) therapies are first‐line therapies for children with inflammatory bowel disease (IBD) (Crohn's disease [CD], ulcerative colitis [UC] and IBD‐unclassified [IBD‐U]). Limited studies describing anti‐TNFs durability and loss of response in children. This study evaluates predictors of primary Nonresponse and 3‐year drug durability in children with IBD.Methods: This was a single‐center retrospective review of patients with IBD less than 18 years old who initiated anti‐TNF (infliximab or adalimumab) from January 1, 2014, to December 31, 2019. Clinical and laboratory data were recorded at the time of anti‐TNF initiation, 14 weeks, 12 months, and 3 years. Predictors of primary nonresponse (discontinuation within 14 weeks) and durability were assessed.Results: A total of 456 patients initiated anti‐TNF therapy (183 adalimumab and 273 infliximab). Thirty‐seven (8%) patients were primary nonresponders. The 3‐year drug durability for both therapies was >70%. Among patients with CD, the 3‐year durability was >75% for both therapies. The 3‐year durability with UC/IBD‐U was 37% for adalimumab and 56% for infliximab. Predictors of primary nonresponse were an erythrocyte sedimentation rate > 55 mm/h in CD on infliximab, and baseline albumin <4 g/dL and 75% in patients with CD, while the durability was lower (37%–56%) for patients with UC/IBD‐U. Less than 10% of patients were considered primary nonresponders, which lends support to the long‐term durability of anti‐TNF therapies for pediatric IBD while keeping in mind predictive factors of Nonresponse.
- Open Access
Infliximab Biosimilar Utilization in a Large Pediatric Learning Health System
Background/Objectives: Infliximab biosimilars entered the United States (US) market in November 2016. Uptake of infliximab biosimilars has been slow in adult studies. We aimed to assess variation in the initiation of infliximab biosimilars in a large pediatric cohort. Methods: We performed a retrospective cohort study using data from 2016 to 2023 prospectively collected by the ImproveCareNow (ICN) Network, a multicenter pediatric inflammatory bowel disease (IBD) quality improvement collaborative. Pediatric patients with IBD who started any infliximab therapy were included. Descriptive statistics were used to summarize patient characteristics and changes in the use of infliximab agents. Chi-square or Fisher’s exact tests were used to evaluate differences in infliximab biosimilar initiation over time by race, age, ethnicity, and region. Results: In total, 4602 patients from 73 ICN centers started an infliximab agent. Infliximab biosimilar initiation rose steadily from 1% in 2018 to nearly 42% in 2023, with 88% of centers using biosimilars in 2023. Overall, from 2016 to 2023, the total percentage of patients who were started on an infliximab biosimilar was 17.3%. There were no differences in infliximab biosimilar initiation by age, race, or ethnicity, except in 2020 for age and race. The Midwest, West, and Southwest regions had higher initiation rates of infliximab biosimilars than the rest of the US. Conclusions: The percentage of patients with IBD initiating an infliximab biosimilar rose slowly to nearly 42% by 2023, and eight (12%) centers never recorded prescribing an infliximab biosimilar in the ICN Network. There were no differences in biosimilar initiation based on race or ethnicity.
Open AccessInfliximab Biosimilar Utilization in a Large Pediatric Learning Health System
Background/Objectives: Infliximab biosimilars entered the United States (US) market in November 2016. Uptake of infliximab biosimilars has been slow in adult studies. We aimed to assess variation in the initiation of infliximab biosimilars in a large pediatric cohort. Methods: We performed a retrospective cohort study using data from 2016 to 2023 prospectively collected by the ImproveCareNow (ICN) Network, a multicenter pediatric inflammatory bowel disease (IBD) quality improvement collaborative. Pediatric patients with IBD who started any infliximab therapy were included. Descriptive statistics were used to summarize patient characteristics and changes in the use of infliximab agents. Chi-square or Fisher’s exact tests were used to evaluate differences in infliximab biosimilar initiation over time by race, age, ethnicity, and region. Results: In total, 4602 patients from 73 ICN centers started an infliximab agent. Infliximab biosimilar initiation rose steadily from 1% in 2018 to nearly 42% in 2023, with 88% of centers using biosimilars in 2023. Overall, from 2016 to 2023, the total percentage of patients who were started on an infliximab biosimilar was 17.3%. There were no differences in infliximab biosimilar initiation by age, race, or ethnicity, except in 2020 for age and race. The Midwest, West, and Southwest regions had higher initiation rates of infliximab biosimilars than the rest of the US. Conclusions: The percentage of patients with IBD initiating an infliximab biosimilar rose slowly to nearly 42% by 2023, and eight (12%) centers never recorded prescribing an infliximab biosimilar in the ICN Network. There were no differences in biosimilar initiation based on race or ethnicity.
- Open Access
- 18 January 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (1) , 214
T Cell-Induced Colitis Is Exacerbated by Prolonged Stress: A Comparison in Male and Female Mice
Psychological stress exposure is well recognized to exacerbate inflammatory bowel disease (IBD) but the mechanisms involved remain poorly understood. In this study, chronic T cell-mediated colitis was induced by adoptively transferring CD4+CD45RBhigh splenic T cells from C57BL/6 WT donor mice into Rag1tm1Mom mice. Two weeks after T cell transfer, mice were exposed to a prolonged restraint stressor (RST) for 8 h per day for 6 consecutive days. The colitis phenotype was assessed via histopathology and semi-quantitative rt-PCR at humane endpoints or 10 weeks post-T-cell transfer. Mice that received the T cell transplant developed chronic colitis marked by increases in colonic histopathology and inflammatory cytokines. Colonic histopathology was greater in males than females regardless of RST exposure but RST exposure increased histopathology scores in females such that they reached scores observed in the males. This pattern was consistent with cytokine gene expression and protein levels in the colon (especially for IFN-γ, IL-17A, and TNF-α). Serum cytokine levels were not strongly affected by exposure to the stressor. Using a murine model of chronic T cell-mediated colitis, this study demonstrates that biological sex strongly influences colonic inflammation and exposure to chronic stress has a more pronounced effect in females than in males.
- 18 January 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (1) , 214
Open AccessT Cell-Induced Colitis Is Exacerbated by Prolonged Stress: A Comparison in Male and Female Mice
Psychological stress exposure is well recognized to exacerbate inflammatory bowel disease (IBD) but the mechanisms involved remain poorly understood. In this study, chronic T cell-mediated colitis was induced by adoptively transferring CD4+CD45RBhigh splenic T cells from C57BL/6 WT donor mice into Rag1tm1Mom mice. Two weeks after T cell transfer, mice were exposed to a prolonged restraint stressor (RST) for 8 h per day for 6 consecutive days. The colitis phenotype was assessed via histopathology and semi-quantitative rt-PCR at humane endpoints or 10 weeks post-T-cell transfer. Mice that received the T cell transplant developed chronic colitis marked by increases in colonic histopathology and inflammatory cytokines. Colonic histopathology was greater in males than females regardless of RST exposure but RST exposure increased histopathology scores in females such that they reached scores observed in the males. This pattern was consistent with cytokine gene expression and protein levels in the colon (especially for IFN-γ, IL-17A, and TNF-α). Serum cytokine levels were not strongly affected by exposure to the stressor. Using a murine model of chronic T cell-mediated colitis, this study demonstrates that biological sex strongly influences colonic inflammation and exposure to chronic stress has a more pronounced effect in females than in males.
- 20 September 2023
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 77 (4) , 499-504
Similar Growth Outcomes in Children with Inflammatory Bowel Disease Initiated on Infliximab Originator or Biosimilar
Background: Growth is an important clinical outcome, especially in childhood‐onset inflammatory bowel disease (IBD). Prior research has demonstrated growth improvements with infliximab therapy. There are limited studies evaluating whether clinical and growth outcomes in children initiated on the infliximab originator and infliximab biosimilar are similar.Methods: This was a single‐center retrospective review of patients with IBD, younger than 17 years old, and initiated on the infliximab originator or biosimilar for at least 12 months between April 2016 and February 2021. Propensity score matching was utilized. Laboratory values, disease activity scores, and growth values were collected at baseline (prior to infliximab initiation), 6 months, and 12 months post initiation. Linear mixed models with random intercepts were used to test differences in measures over time and between study groups.Results: There were 113 patients on the originator and 39 patients on a biosimilar who met eligibility criteria. Propensity score methodology identified 37 dyads (1:1 match). Weight, height, and body mass index z scores increased over time (from baseline to 12 months) for both groups (P < 0.05) and there was a similar rate of change between study groups. Clinical outcomes of lab values (albumin, C‐reactive protein, and hemoglobin) and disease activity scoring were similar from baseline to 12 months between study groups.Conclusions: There were similar improvements in growth and clinical outcomes in patients initiated on the infliximab originator compared to an infliximab biosimilar agent. This study adds to the limited research evaluating whether infliximab biosimilars have similar growth outcomes in children with IBD.
- 20 September 2023
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 77 (4) , 499-504
Similar Growth Outcomes in Children with Inflammatory Bowel Disease Initiated on Infliximab Originator or Biosimilar
Background: Growth is an important clinical outcome, especially in childhood‐onset inflammatory bowel disease (IBD). Prior research has demonstrated growth improvements with infliximab therapy. There are limited studies evaluating whether clinical and growth outcomes in children initiated on the infliximab originator and infliximab biosimilar are similar.Methods: This was a single‐center retrospective review of patients with IBD, younger than 17 years old, and initiated on the infliximab originator or biosimilar for at least 12 months between April 2016 and February 2021. Propensity score matching was utilized. Laboratory values, disease activity scores, and growth values were collected at baseline (prior to infliximab initiation), 6 months, and 12 months post initiation. Linear mixed models with random intercepts were used to test differences in measures over time and between study groups.Results: There were 113 patients on the originator and 39 patients on a biosimilar who met eligibility criteria. Propensity score methodology identified 37 dyads (1:1 match). Weight, height, and body mass index z scores increased over time (from baseline to 12 months) for both groups (P < 0.05) and there was a similar rate of change between study groups. Clinical outcomes of lab values (albumin, C‐reactive protein, and hemoglobin) and disease activity scoring were similar from baseline to 12 months between study groups.Conclusions: There were similar improvements in growth and clinical outcomes in patients initiated on the infliximab originator compared to an infliximab biosimilar agent. This study adds to the limited research evaluating whether infliximab biosimilars have similar growth outcomes in children with IBD.